BeStock  
Stocks › Biotechnology › SLN

Silence Therapeutics SLN

US equityMarket cap rank #3022Biotechnology
$19.81 +$0.00 (0.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $19.81 0.00%
Open$19.81
Prev close$19.81
Day range$19.80 – $19.83
Volume399.1K
Market cap$1.23B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-18.9x
CheapRich

Near the bottom of its 5-year range · 0th percentile, 5-year average -7.8x

Price / book-5.7x
CheapRich

Near the bottom of its 5-year range · 6th percentile, 5-year average 11.3x

#5189 of 5329 stocks by PB (1 = cheapest)

Price / sales2,705.0x
CheapRich

Near the top of its 5-year range · 100th percentile, 5-year average 135.8x

#5117 of 5156 stocks by PS (1 = cheapest)

P/E over five years

-21x-14x-7x-1xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$23.98
Price vs. fair value-17.4%Trading below the estimate
Star rating★★★☆☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB -5.74 – 11.30 6% (cheaper than usual) #5189 of 5329 (1 = cheapest)
PE -18.89 -17.95 -7.81 0% (cheaper than usual) –
PS 2,705.01 1,393.58 135.79 100% (pricier than usual) #5117 of 5156 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on SLN.

Sign in to join the discussion.

Scroll to Top